Patient-specific human immune system-bearing mouse model created by implanting human thymic cells derived from iPSC with Tolerance Bio’s proprietary process Human T cells educated in vivo by thymic organoids delayed melanoma tumor growth in a patient derived xenograft model Data support the development of Tolerance Bio’s thymic cells and pharmacological…
Read More
Tolerance Bio and ZipCode Bio Announce Strategic R&D Collaboration to Advance Targeted Thymus Therapeutics September 8, 2025 10:30 AM, PHILADELPHIA & BOSTON--(BUSINESS WIRE)--Tolerance Bio, a biopharmaceutical company pioneering innovative approaches to extending healthspan by preserving, restoring, and manipulating the function of the thymus, the master regulator of immune tolerance, and…
Read More
Tolerance Bio, Inc. Announces Scientific Advisory Board and Completion of $20.2 Million Seed Round to Advance Thymus-Based Therapies for Immune-Mediated Diseases World-class leaders in the thymus, immunology, oncology, cell therapy, and drug development will inform and support the Company’s efforts to preserve, restore, and manipulate the thymus to address…
Read More
Tolerance Bio, Inc. Launches With $17.2 Million in Seed Financing to Advance Thymus-Based Therapies for Immune-Mediated Diseases Led by industry innovator Francisco Leon, M.D., Ph.D., Tolerance Bio is developing thymus preservation, regeneration, and manipulation platforms to prevent and treat immune diseases Financing led by Columbus Venture Partners, with participation by…
Read More